Syndax Announces Participation in February Investor Conferences

WALTHAM, Mass., Jan. 30, 2025 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer of Syndax, as well as members of the Syndax management team, will participate in the following upcoming investor conferences: Guggenheim SMID Cap Biotech Conference in New York, NY with a fireside chat on Thursday, February 6, 2025, at 10:30 a.m. ET Citi's 2025 ...